Simon J Little
Lawyers
Filters
LivaNova $345 million convertible notes offering and capped call transactions
The 2.5% convertible senior notes are due 2029
Immunocore Holdings $402.5 million convertible notes offering
The 2.5% convertible notes are due 2030
TP Global Operations acquisition of Truphone’s non-Russian business and assets
We advised the acquirer of Truphone’s assets in a pre-packaged English administration
Avianca $1.05 billion DIP-to-exit financing
We advised an ad hoc group of investors on Avianca’s DIP-to-exit financing
NYDIG acquires Bottlepay
We are advising NYDIG on the transaction
Sixjoy Hong Kong £919 million offer for Sumo Group
We are advising Tencent on the recommended cash offer by its indirect subsidiary
Gyroscope Therapeutics $148.0 million Series C equity financing
We advised Gyroscope Therapeutics on its private placement of preferred stock
Royalty Pharma $728 million secondary offering
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…
Royalty Pharma $6 billion senior notes offering
Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its 0.75% senior notes due 2023, $1 billion…
Freeline Therapeutics Holdings $158.8 million IPO
Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…